280
P A R T 3
Drugs acting on the immune system
TABLE 18.1
DRUGS IN FOCUS Vaccines (continued)
Drug name
Dosage/route
Usual indications
Toxoids
diphtheria and tetanus toxoid
(ADT Booster)
0.5 mL IMI
Reimmunisation in adults and children
>5 years
diphtheria and tetanus toxoid
and pertussis vaccine (Adacel,
Boostrix)
0.5 mL deep IMI
Immunisation in adults and children
>10 years
diphtheria and tetanus toxoid and
pertussis vaccine (Tripacel)
0.5 mL IMI at 2, 4, 6, 18 months and
booster 4–6 years
Primary immunisation children 6 weeks
or older
diphtheria and tetanus toxoid,
pertussis and poliomyelitis
vaccine (Adacel Polio, Boostrix-
IPV, Quadracel)
0.5 mL deep IMI
Booster immunisation in adults or
children >4 years
diphtheria and tetanus toxoid,
pertussis and poliomyelitis
vaccine (Infanrix IPV )
0.5 mL by deep IMI
Primary immunisation in children
6 weeks or older
diphtheria and tetanus toxoid,
and hepatitis B, pertussis and
poliomyelitis vaccine (Infanrix
Penta)
0.5 mL IM at 2, 4, 6 months
Primary immunisation in children
6 weeks or older
diphtheria and tetanus toxoid,
and hepatitis B, pertussis,
poliomyelitis and Haemophilus
influenzae vaccine (Infanrix
Hexa)
0.5 mL IM at 2, 4, 6 months
Primary immunisation in children
6 weeks or older
Viral vaccines
H1N1 pandemic influenza vaccine
(Panvax)
Adult or paediatric >36 months: 0.5 mL IMI
or deep SC
Paediatric 6–35 months: 0.25 mL IMI or
deep SC
Adults and paediatric >10 years: single
dose
Paediatric 6 months–10 years: 2 doses at
least 4 weeks apart
Active immunisation against H1N1
influenza
hepatitis A vaccine, inactivated
(Avaxim, Havrix,VAQTA)
Adult: 1 mL IM with a booster dose in
6–12 months
Paediatric: 0.5 mL IM with a repeat dose
in 6–12 months
Immunisation of adults and children
against hepatitis A infection
hepatitis A vaccine, inactivated,
with hepatitis B recombinant
vaccine (Twinrix)
1 mL IM followed by booster doses at
1 and 6 months
Immunisation against hepatitis A
and hepatitis B infections in people
≥18 years of age
hepatitis B vaccine (Energix-B,
H-B-Vax II)
0.5–1 mL IM, followed by 0.5–1 mL IM at
1 and 6 months
Immunisation against hepatitis B
infections in susceptible people
and in infants born to mothers with
hepatitis B
human papillomavirus,
recombinant, quadrivalent
(Cervarix, Gardasil)
Females 9–26 years: 0.5 mL IM, then
0.5 mL IM 2 months later, followed by
0.5 mL IM 6 months after the first dose
Active immunisation against human
papillomavirus responsible for
causing genital warts and many
cervical cancers
influenza virus vaccine (Fluarix,
Fluvax)
Adult: 0.5 mL IM or deep SC
Paediatric: 0.25–0.5 mL IM or deep SC,
repeated in 4 weeks
Prophylaxis in adults and children
at high risk for complications of
influenza infections
Japanese encephalitis vaccine
(Je-Vax)
1 mL SC on days 0, 7 and 30
1–3 years: 0.5 mL SC on days 0, 7 and 30
Immunisation of persons >1 year of
age who reside in or will travel to
endemic areas
